11th Annual meeting of the EBMT pp 147-147 | Cite as
In vitro Treatment of Marrow with ATCG or Campath-1 for Prophylaxis of GVHD
Abstract
Graft-versus-host disease (GVHD) is a major obstacle of allogeneic bone marrow transplantation. Presumably mature T-lymphocytes in the marrow graft are responsible for the GVH reaction resulting in GVHD. We have studied removal of T-lymphocytes by treatment of the marrow with absorbed antithymocyte globulin (ATCG) and recently monoclonal antibodies for prevention of GVHD in mice, dogs and man (Rodt et al. 1972, Kolb et al. 1979, Thierfelder et al. 1984). Crossreacting antibodies against hemopoietic stem cells were removed by absorption with liver, kidney, red cells and B-lymphocytes. Campath 1 is a monoclonal antibody produced in a rat hybridoma that reacts against all human lymphocytes and fixes human complement (Hale et al.1983).
Keywords
Graft Failure Total Body Irradiation Allogeneic Bone Marrow Transplantation Antibody Treatment Hemopoietic Stem CellReferences
- Rodt H. et al. Blut 25: 385, 1972PubMedCrossRefGoogle Scholar
- Kolb H.J. et al. Transplant. 27: 242, 1979CrossRefGoogle Scholar
- Thierfelder S. et al. Exp. Hematol. 12: 373, 1984Google Scholar
- Hale G. et al. Blood 62: 873, 1983PubMedGoogle Scholar